Cite
Frishberg Y, Deschênes G, Groothoff JW, et al. Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial. Clin J Am Soc Nephrol. 2021;16(7):1025-1036doi: 10.2215/CJN.14730920.
Frishberg, Y., Deschênes, G., Groothoff, J. W., Hulton, S. A., Magen, D., Harambat, J., Van't Hoff, W. G., Lorch, U., Milliner, D. S., Lieske, J. C., Haslett, P., Garg, P. P., Vaishnaw, A. K., Talamudupula, S., Lu, J., Habtemariam, B. A., Erbe, D. V., McGregor, T. L., Cochat, P. (2021). Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial. Clinical journal of the American Society of Nephrology : CJASN, 16(7), 1025-1036. https://doi.org/10.2215/CJN.14730920
Frishberg, Yaacov, et al. "Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial." Clinical journal of the American Society of Nephrology : CJASN vol. 16,7 (2021): 1025-1036. doi: https://doi.org/10.2215/CJN.14730920
Frishberg Y, Deschênes G, Groothoff JW, Hulton SA, Magen D, Harambat J, Van't Hoff WG, Lorch U, Milliner DS, Lieske JC, Haslett P, Garg PP, Vaishnaw AK, Talamudupula S, Lu J, Habtemariam BA, Erbe DV, McGregor TL, Cochat P. Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial. Clin J Am Soc Nephrol. 2021 Jul;16(7):1025-1036. doi: 10.2215/CJN.14730920. Epub 2021 May 13. PMID: 33985991; PMCID: PMC8425611.
Copy
Download .nbib